Drug Profile

SKG 0201

Alternative Names: SKG-0201

Latest Information Update: 05 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Skyline Therapeutics
Class Spinal muscular atrophy gene therapies
Mechanism of Action Gene transference; Survival of motor neuron 1 protein replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Spinal muscular atrophy

Most Recent Events

28 Apr 2026 Lanyue Biotech plans a phase I/II trial for Spinal muscular atrophies of childhood (In infants, In neonates) in China (Parenteral, Injection) (NCT07554924) in May 2026
25 Jun 2023 Phase-I clinical trials in Spinal muscular atrophy (In children, In neonates) in China (IV) (NCT06191354)
03 May 2023 Preclinical trials in Spinal muscular atrophy in China (IV), prior to May 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com